The ATP citrate lyase (ACLY) serves as the initial rate-limiting enzyme in de novo lipogenesis, exhibiting high expression levels in both hepatocellular carcinoma (HCC) tissues and liver cancer stem cells (LTICs). This evidence concerns the gene ACLY and hepatocellular carcinoma.